Integra LifeSciences Announces Key Executive Leadership Appointments

Rhea-AI Summary

Integra LifeSciences (Nasdaq: IART) announced Feb 17, 2026 executive appointments: Teshtar Elavia named corporate vice president and newly created chief technology officer, Michael Hutchinson appointed executive vice president and chief legal officer, and Kerri DiPietro named corporate vice president and chief quality officer.

The CTO role will align R&D with strategic imperatives, accelerate product development, and strengthen the innovation pipeline; Hutchinson will lead legal, compliance and ESG; DiPietro will oversee global quality and a Compliance Master Plan.

Positive

• New CTO role created to centralize R&D and accelerate product development
• Teshtar Elavia brings >20 years of R&D experience across major MedTech firms
• Michael Hutchinson has led legal on >80 acquisitions and integrations

Negative

• None.

News Market Reaction

+1.06%

2 alerts

+1.06% News Effect

+$10M Valuation Impact

$945M Market Cap

0.2x Rel. Volume

On the day this news was published, IART gained 1.06%, reflecting a mild positive market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $10M to the company's valuation, bringing the market cap to $945M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Industry experience: more than 20 years

1 metrics

Industry experience more than 20 years Teshtar Elavia new CTO role experience in MedTech fields

Market Reality Check

Price: $12.05 Vol: Volume 695,785 is roughly...

normal vol

$12.05 Last Close

Volume Volume 695,785 is roughly in line with the 20-day average of 713,132. normal

Technical Price at 11.32 is trading below the 200-day MA of 13.15, reflecting a longer-term downtrend.

Peers on Argus

IART gained 4.72% while sector peers showed mixed moves: SSII +8.84%, ESTA +2%, ...

1 Up 1 Down

IART gained 4.72% while sector peers showed mixed moves: SSII +8.84%, ESTA +2%, BBNX +3.11%, AHCO +0.1%, and INMD -1.17%. Momentum scanner names were also split, with ENOV up and SSII down, supporting a stock-specific reaction.

Historical Context

5 past events · Latest: Feb 09 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 09	Earnings call notice	Neutral	-2.9%	Scheduled date and time for Q4 and full-year 2025 results call.
Jan 05	Conference presentation	Neutral	+4.5%	Planned leadership presentation at J.P. Morgan Healthcare Conference.
Dec 01	Conference presentation	Neutral	+0.8%	CEO and CFO participation at Citi 2025 Global Healthcare Conference.
Nov 25	Reimbursement policy	Positive	+6.2%	CMS rules adding all Integra skin substitutes with uniform reimbursement.
Nov 11	Regulatory clearance	Positive	+1.2%	FDA 510(k) clearance expanding CUSA Clarity use in cardiac surgeries.

Pattern Detected

Recent positive regulatory and policy updates have generally seen aligned positive price reactions, with occasional divergence on neutral conference-related news.

Recent Company History

Over the past few months, Integra has reported several notable developments. A Nov 11, 2025 FDA 510(k) clearance for CUSA Clarity and the Nov 25, 2025 Medicare reimbursement policy improvements both saw positive next-day moves. Conference participation and an earnings call announcement in late 2025 and early 2026 produced smaller, mixed reactions. Today’s executive leadership appointments extend this pattern of operational and strategic updates focused on growth, quality, and innovation.

Market Pulse Summary

This announcement details three senior leadership appointments, including a newly created chief tech...

Analysis

This announcement details three senior leadership appointments, including a newly created chief technology officer role to oversee R&D and innovation. The move follows recent regulatory and reimbursement milestones, such as FDA 510(k) clearance and favorable Medicare policy in late 2025. Investors may watch how the new CTO, chief legal officer, and chief quality officer influence product development, compliance, and quality systems as the company trades near 6.79% above its 52-week low.

Key Terms

research and development, esg, post-market surveillance, quality management system

4 terms

research and development technical

"a newly created position to lead research and development (R&D), including product"

Research and development is the work a company does to discover, test and improve new products, services or processes. Think of it as planting seeds for future growth: it costs money now but can create competitive advantages, new revenue streams or regulatory approvals later, so investors watch R&D spending and progress to judge a company's future growth potential and the risk that those investments may or may not pay off.

esg financial

"global legal, compliance, and environmental, social and governance (ESG) functions"

ESG stands for Environmental, Social, and Governance, which are key factors investors consider when evaluating how sustainable and responsible a company is. It involves assessing how a company manages its impact on the environment, treats its employees and communities, and operates transparently and ethically. Investors use ESG criteria to identify businesses that align with their values and have the potential for long-term success.

post-market surveillance regulatory

"including design assurance, post-market surveillance, supplier quality, complaint handling"

Post-market surveillance is the ongoing monitoring of a product’s safety and performance after it has been approved and sold, especially for drugs and medical devices. Like watching cars after they leave the showroom to catch hidden defects, it matters to investors because problems discovered later can trigger recalls, regulatory fines, extra testing, or damaged reputation — all of which can reduce future sales and hurt a company’s financial outlook.

quality management system technical

"strengthening and harmonization of the global quality management system"

A quality management system is an organized set of policies, procedures and records a company uses to ensure its products or services consistently meet required standards and regulations. Investors care because a strong system reduces the risk of product failures, recalls, regulatory fines and costly delays, much like a well-maintained checklist and routine for a kitchen that keeps meals safe and on schedule, protecting reputation and predictable earnings.

AI-generated analysis. Not financial advice.

Executive team further strengthened with appointments of Teshtar Elavia to the newly created chief technology officer role, Michael Hutchinson as chief legal officer, and Kerri DiPietro as chief quality officer, representing decades of experience in the MedTech industry

PRINCETON, N.J., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced the appointment of Teshtar Elavia as corporate vice president and chief technology officer, a newly created position to lead research and development (R&D), including product and technology development, across the company. The company also announced the appointments of Michael Hutchinson as executive vice president, chief legal officer and secretary, and Kerri DiPietro as corporate vice president and chief quality officer.

The creation of the chief technology officer (CTO) position underscores Integra’s commitment to building a more connected innovation engine to advance long-term growth. As CTO, Teshtar Elavia will work to align R&D priorities with the company’s strategic imperatives, accelerate the impact and speed of product development programs, and strengthen the company’s innovation pipeline through organic and partnership efforts. He will also help identify emerging trends and technologies that reinforce the company’s market leadership and provide opportunities for future growth.

Elavia brings more than 20 years of experience in new product development spanning imaging and navigation, minimally invasive surgery, regenerative medicine, diabetes care, and autoimmune diseases, with senior R&D leadership roles at Becton Dickinson, Eli Lilly, Medtronic, and Johnson & Johnson. Most recently, he served as vice president of R&D for Becton Dickinson’s Medical Delivery Solutions business, where he led the development of an R&D roadmap to drive growth in high-value markets and advanced connected care innovation initiatives.

Michael Hutchinson will lead the company’s global legal, compliance, and environmental, social and governance (ESG) functions and serve as the principal legal advisor to the executive leadership team and board of directors. He is a seasoned attorney and business leader with more than 20 years of experience spanning complex litigation, corporate governance, risk management, ESG matters, and more than 80 acquisitions and integrations. Prior to joining Integra, Hutchinson served as senior vice president and chief legal officer at LivaNova, with prior chief legal officer roles at Stryker and Varian Medical Systems.

Kerri DiPietro will lead Integra’s global quality organization, driving the execution of the company’s enterprise-wide Compliance Master Plan and overseeing the strengthening and harmonization of the global quality management system. Her responsibilities will encompass all global quality activities, including design assurance, post-market surveillance, supplier quality, complaint handling, and validation. DiPietro joins Integra from Haemonetics, where she served as senior vice president of global quality and compliance, and led transformational improvements in product quality, regulatory compliance, and global quality system integration.   Prior to Haemonetics, she was at Boston Scientific, where she held roles of increasing responsibility in R&D, operations and quality.

“Creating a dedicated chief technology officer role is a decisive step in how we are building Integra for the future,” said Mojdeh Poul, president and CEO of Integra LifeSciences. “Innovation is a core strategic imperative for us, and Teshtar brings deep experience translating emerging technologies into impactful solutions. Together with the additions of Kerri and Mike, these appointments reflect our commitment to assembling a seasoned, highly respected leadership team that can deliver our transformation and drive long-term value.”

Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties and reflect the Company's judgment as of the date of this release. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements. These forward-looking statements relate to, among other things, expectations, estimates and projections concerning the Company’s business and operations, financial performance, strategic initiatives and product development and the responsibilities and impact of the newly appointed executives. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ from predicted results. These risks and uncertainties include, without limitation, the ability of the Company to successfully integrate new executives and to execute its business plan and achieve long-term business, financial, operational and strategic targets, other factors beyond the Company's control, and the economic, competitive, governmental, technological, and other factors identified under the heading "Risk Factors" included in item 1A of Integra's Annual Report on Form 10-K for the year ended December 31, 2024, and information contained in subsequent filings with the Securities and Exchange Commission. These forward-looking statements are made only as of the date hereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events, or otherwise, except as otherwise required by law.

About Integra LifeSciences
Integra LifeSciences (Nasdaq: IART) is a global medical technology leader dedicated to restoring lives. We are advancing transformational care through impactful innovation in neurosurgery and tissue reconstruction, specialized fields that demand exceptional expertise and precision. Our portfolio of highly differentiated, gold-standard products and solutions is trusted by healthcare professionals to improve patient outcomes. For the latest news and information about Integra and its products, please visit www.integralife.com.

Investor Relations:
Chris Ward
(609) 772-7736
chris.ward@integralife.com

Media:
Laurene Isip
(609) 208-8121
laurene.isip@integralife.com

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/1782feaf-4737-4559-b7a4-a14751a9a911

https://www.globenewswire.com/NewsRoom/AttachmentNg/19201093-4d6e-49e3-b19a-939a152b9fab

https://www.globenewswire.com/NewsRoom/AttachmentNg/ced57248-f8eb-4e04-ab6c-bc3deba74a85 

FAQ

What will Teshtar Elavia do as Integra (IART) chief technology officer?

Elavia will lead R&D and product and technology development across Integra to align with strategy. According to the company, he will accelerate product development, strengthen the innovation pipeline, and identify emerging trends and technologies to support market leadership and growth.

How does the new CTO role affect Integra's (IART) R&D priorities?

The CTO will centralize and align R&D priorities with company strategy to speed development. According to the company, this role is intended to accelerate program impact, foster organic and partnership innovation, and better connect technology efforts to long-term growth.

What are Michael Hutchinson's responsibilities as Integra (IART) chief legal officer?

Hutchinson will lead global legal, compliance, and ESG functions and serve as principal legal advisor. According to the company, he brings experience in complex litigation, governance, risk management, and has worked on more than 80 acquisitions and integrations.

What will Kerri DiPietro oversee as Integra's (IART) chief quality officer?

DiPietro will lead the global quality organization and execute the Compliance Master Plan. According to the company, her scope includes design assurance, post-market surveillance, supplier quality, complaint handling, validation, and harmonizing the global quality system.

What do these leadership hires signal for Integra (IART) investors?

The appointments signal a focus on innovation, quality, and governance to support long-term value creation. According to the company, creating a CTO and hiring experienced legal and quality leaders is intended to strengthen execution of the company’s transformation and strategic priorities.